Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14068090 | 1.00 | SIGMAR1 (0.44) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL14068095 | 0.88 | HSD11B1 (0.49) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL14068096 | 0.88 | HSD11B1 (0.49) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL18194529 | 0.88 | SIGMAR1 (0.43) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL18194530 | 0.88 | SIGMAR1 (0.43) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL14068010 | 0.86 | SIGMAR1 (0.55) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL14068033 | 0.86 | SIGMAR1 (0.55) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL14077008 | 0.79 | SRD5A1 (0.38) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL18780082 | 0.74 | SRD5A1 (0.38) | SIGMAR1SRD5A1HSD11B1 | |
| SCHEMBL14068084 | 0.73 | SIGMAR1 (0.54) | SIGMAR1SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563591-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-22 | — | — | US | claimed |
| EP-1786774-B1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-14 | — | — | EP | claimed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | claimed |
| EP-1786774-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-23 | — | — | EP | claimed |
| WO-2006024628-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | claimed |
| US-9630921-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-25 | — | — | US | disclosed |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-9422284-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20160002229-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | disclosed |
| US-9150512-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-10-06 | — | — | US | disclosed |
| US-20140179732-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-26 | — | — | US | disclosed |
| US-8563591-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-22 | — | — | US | disclosed |
| EP-1786774-B1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-14 | — | — | EP | disclosed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | disclosed |
| EP-1786774-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024628-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002229-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SIGMAR1 2693/4885SRD5A1 17/4885HSD11B1 3/4885 |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | CHRM1, CHRNA7, CHRM5 | SIGMAR1 191/4885SRD5A1 254/4885HSD11B1 136/4885 |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SIGMAR1 2693/4885SRD5A1 17/4885HSD11B1 3/4885 |
| US-20140179732-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SIGMAR1 2693/4885SRD5A1 17/4885HSD11B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.